Technical analysis of Denali Therapeutics Inc. (DNLI): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline.
Price Performance
| 1 month | -5.30% |
| 3 months | -21.64% |
| Year-to-date | +14.72% |
| 1 year | +16.34% |
| 3 years | -13.24% |
| 5 years | -64.38% |
52-Week Range
| 52-week High | $27.30 |
| 52-week Low | $13.75 |
| Avg Volume (90d) | 1.7M |
Technical Indicators
| SMA 50 | $20.64 |
| SMA 200 | $21.23 |
| Beta | 1.10 |
| 30-day Volatility (annualised) | 42.7% |
| Price vs SMA 50 | -8.2% |
| Price vs SMA 200 | -10.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $16.51 | |
| 2026-01 | $21.74 | +31.7% |
| 2026-02 | $21.18 | -2.6% |
| 2026-03 | $19.20 | -9.3% |
| 2026-04 | $18.72 | -2.5% |
| 2026-05 | $21.04 | +12.4% |
| 2026-06 | $25.72 | +22.2% |
| 2026-07 | $23.02 | -10.5% |
| 2026-08 | $23.76 | +3.2% |
| 2026-09 | $20.67 | -13.0% |
| 2026-10 | $18.94 | -8.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-03 | $-0.32 | $12M |
| 2026-08-06 | $-0.51 | $2M |
| 2026-05-07 | $-0.73 | $3M |
| 2026-02-26 | $-0.75 | $3M |
| 2025-11-06 | $-0.76 | $3M |
| 2025-08-11 | $-0.74 | $6M |
| 2025-05-06 | $-0.71 | $3M |
Price
| Price | $18.94 (closing price, October 30, 2026) |
| Market Cap | $3.0B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 4.25 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 8.37 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 9.99 |